| Dear Fellow Investor, Here are three "Strong Buy" healthcare stocks from Wall Street- Elevance Health, Inc. – SYM: ELV
Recent Price: $484.82
Price Target: $578.13
Firms with Buy Rating: J.P. Morgan, Goldman Sachs, Bank of America
Description: Elevance Health, Inc. operates as a health benefits company. The company operates through four segments: Commercial & Specialty Business, Government Business, CarelonRx, and Other. Smart investors are turning to the global mining sector — and particularly the small-cap exploration stocks that are stepping up to procure the key metals needed in the green-energy revolution. A big focus is on the Platinum Group Metals — or PGMs — that are fueling the global rise in electric vehicles (EVs). Click here and the name & symbol are yours! McKesson Corporation – SYM: MCK
Recent Price: $362.46
Price Target: $428.91
Firms with Buy Rating: J.P. Morgan, Morgan Stanley, Bank of America
Description: McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas. Thermo Fisher Scientific Inc. – SYM: TMO
Recent Price: $551.87
Price Target: $654.27
Firms with Buy Rating: Morgan Stanley, J.P. Morgan, Citigroup
Description: Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts. Achieve consistent 50-70% gains with a proven system that has a win rate of 97%. Don't miss out, download your copy of the latest eBook now and start thriving in any market condition. Click here! Behind the Markets is brought to you by Behind the Markets, LLC. If you have any questions, please contact us at support@behindthemarkets.com, or call at 800-851-1965. Behind the Markets is a newsletter offered to the public on a subscription basis. While subscribers receive the benefit of Behind the Markets opinions, none of the information contained therein constitutes a recommendation from Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Behind the Markets may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Behind the Markets’ past results are not necessarily indicative of future performance.
Employees of Behind the Markets are subject to certain restrictions in transacting for their own benefit. SPECIFICALLY, EMPLOYEES ARE NOT PERMITTED TO BUY OR SELL ANY SECURITY RECOMMENDED FOR THREE (3) TRADING DAYS FOLLOWING THE ISSUE OF A REPORT OR UPDATE.
Behind the Markets’ Newsletter contains Behind the Markets’ own opinions, and none of the information contained therein constitutes a recommendation by Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person.
You further understand that Behind the Markets will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter.
To the extent any of the information contained in Behind the Markets Newsletter may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
Behind the Markets’ past results are not necessarily indicative of future performance. DO NOT EMAIL Behind the Markets SEEKING PERSONALIZED INVESTMENT ADVICE, WHICH WE CANNOT PROVIDE.
The Editor's personal investing goals and risk tolerance may be substantially different from those discussed in the Newsletter and/or circumstances may have changed by the expiration of the three day restricted period, the investment actions taken by the Editor in the accounts the Editor directly or indirectly owns may vary from (and may even be contrary to) the advice and recommendations in the Newsletter.
Investing involves substantial risk. Neither the Editor, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from using the Newsletter. While past performance may be analyzed in the Newsletter, past performance should not be considered indicative of future performance.
No subscriber should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing the prospectus and other public filings of the issuer.
To the maximum extent permitted by law, the Editor, the publisher and their respective affiliates disclaim any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations in the Newsletter prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.
The Newsletter's commentary, analysis, opinions, advice and recommendations represent the personal and subjective views of the Editor and are subject to change at any time
without notice.
The information provided in the Newsletter is obtained from sources which the Editor believes to be reliable. However, the Editor has not independently verified or otherwise investigated all such information. Neither the Editor, the publisher, nor any of their respective affiliates guarantees the accuracy or completeness of any such information.
The Newsletter is not a solicitation or offer to buy or sell any securities. Further, the Newsletter is in no way intended to be a solicitation for any services offered by Behind the Markets
Neither the Editor, the publisher, nor any of their respective affiliates are responsible for any errors or omissions in the Newsletter. |
Post a Comment
Post a Comment